Abstract
This single-institution retrospective analysis reviews the management and outcome of patients with surgically treated adenocarcinoma of the duodenum. Between February 1984 and August 1996, fifty-five patients with adenocarcinoma of the duodenum underwent surgery at The Johns Hopkins Hospital. Univariate analysis was performed to identify possible prognostic indicators. Curative resection was performed in 48 patients (87%): 35 of these patients (73%) underwent a pancreaticoduodenectomy (PD), whereas 27% (n = 13) underwent a pancreas-sparing duodenectomy (PSD). Patients undergoing PD were comparable to those undergoing PSD with respect to demographic factors, presenting symptoms, and tumor pathology. The remaining 13% of patients (n = 7) were deemed unresectable at the time of surgery and underwent biopsy and/or palliative bypass. PD was associated with an increase in postoperative complications when compared to PSD (57% vs. 30%), but this difference was not statistically significant. One perioperative death occurred following PD (mortality 2.9%), The overall 5-year survival rate for the 48 patients undergoing potentially curative resection was 53 %. Negative resection margins (P <0.001), PD (P <0.005), and tumors in the first and second portions of the duodenum (P <0.05) were favorable predictors of long-term survival by univariate analysis. Nodal status, tumor diameter, degree of differentiation, and the use of adjuvant chemoradiation therapy did not influence survival. These data support an aggressive role for resection in patients with adenocarcinoma of the duodenum
Similar content being viewed by others
References
Spira IA, Ghazi A, Wolff WI. Primary adenocarcinoma of the duodenum. Cancer 1977;39:1721–1726.
Alwmark A, Andersson A, Lasson A. Primary carcinoma of the duodenum. Ann Surg 1980;191:13–18.
Ouriel K, Adams JT. Adenocarcinoma of the small intestine. AmJ Surg 1984;147:67–71.
Perry BJ. Neoplasms of the duodenum. In Scott HW, Sawyers JL, eds. Surgery of the Stomach, Duodenum, and Small Intestine. Boston: Blaekwell Scientific Publications, 1987, pp 571–584.
Yeo CJ, Cameron JL, Sohn TA, Lillemoe KD, Pitt HA, Ta-lamini MA, Hruban RH, Ord SE, Sauter PK, Coleman J, Za-hurak ML, Grochow LB, Abrams RA. 650 consecutive pancreaticoduodenectomies in the 1990’s: Pathology, complications, outcomes. Ann Surg 1997;226:248–260.
Lowell JA, Rossi RL, Munson JL, Braasch JW. Primary adenocarcinoma of the third and fourth portions of duodenum. Arch Surg 1992;127:557–560.
Joesting DR, Beart RW, van Heerden JA, Weiland LH. Improving survival in adenocarcinoma of the duodenum. Am J Surg 1981;141:228–231.
Sexe RB, Wade TP, V]rgo KS, Johnson FE. Incidence and treatment of periampullary duodenal cancer in the U.S. veteran patient population. Cancer 1996; 77:251–254.
Rose DM, Hochwald SN, Klimstra DS, Brennan ME. Primary duodenal adenocarcinoma: A ten-year experience with 79 patients. J Am Coll Surg 1996;183:89–96.
Rotman N, Pezet D, Fagniez PL, Cherqui D, Celicout B, Lointier E. Adenocarcinoma of the duodenum: Factors influencing survival. BrJ Surg 1994;81:83–85.
Scott-Coombes DM, Williamson RCN. Surgical treatment of primary duodenal carcinoma: A personal series. Br J Surg 1994;81:1472–1474.
Yeo CJ, Cameron JL, Lillemoe KD, Sitzmann JV, Hruban RH, Goodman SN, Dooley WC, Coleman JA, Pitt HA. Pancreaticoduodenectomy for cancer of the head of the pancreas. 201 patients. Ann Surg 1995;221:721–733.
Maher MM, Yeo CJ, Lillemoe KD, Roberts JR, Cameron JL. Pancreas-sparing duodenectomy for infra-ampullary duodenal pathology. AmJ Surg 1996;171:62–67.
Yeo CJ, Barry MK, Sauter PK, Sostre S, Lillemoe KD, Pitt HA, Cameron JL. Erythromycin accelerates gastric emptying after pancreaticoduodenectomy. A prospective, randomized, placebo-controlled trial. Ann Surg 1993;218:229–238.
Yeo CJ, Cameron JL, Maher MM, Sauter PK, Zahurak ML, Talamini MA, Lillemoe KD, Pitt HA. A prospective randomized trial of pancreaticogastrostomy versus pancreaticojejunostomy after pancreaticoduodenectomy. Ann Surg 1995;222:580–592.
Yeo CJ, Abrams RA, Grochow LB, Sohn TA, Ord SE, Zahu-rak ML, Hruban RH, Coleman J, Sauter PK, Pitt HA, Lille-moe KD, Cameron JL. Pancreaticoduodenectomy for pancreatic adenocarcinoma: Postoperative adjuvant therapy improves survival. Ann Surg 1997;225:621–636.
Kaplan E, Meier E. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958;53:457–481.
Michelassi F, Erroi F, Dawson PJ, Pietrabissa A, Noda S, Handcock M, Block GE. Experience with 647 consecutive tumors of the duodenum, ampulla, head of the pancreas, and distal common bile duct. Ann Surg 1989;210:544–556.
CraneJM, Gobbel WG, Scott HW. Surgical experience with malignant tumors of the ampulla of Vater and duodenum. Surg Gynecol Obstet 1973;137:937–940.
Chan C, Herrara MF, de la Garza L, Quintanilla-Martinez L, Vargas-Vorackova F, Richaud-Patfn Y, Llorente L, Uscanga L, Robles-Diaz G, Leon E, Campuzano M. Clinical behavior and prognostic factors of periampullary adenocarcinoma. Ann Surg 1995;222:632–637.
Jones BA, Langer B, Taylor BR, Girottis M. Periampultary tumors: Which ones should be resected? Am J Surg 1985; 149:46–52.
Lai ECS, DotyJE, Irving C, Tompkins RK. Primary adenocarcinoma of the duodenum: Analysis of survival. World J Surg 1988;12:695–699.
van Ooijen B, Kalsbeek HL. Carcinoma of the duodenum. Surg Gynecol Obstet 1988;166:343–347.
Pickelman J, Koelsch M, Chejfec G. Node-positive duodenal carcinoma is curable. Arch Surg 1997; 132:241–244.
Barnes G, Romero L, Hess KR, Curley SA. Primary adenocarcinoma of the duodenum: Management and survival in 67 patients. Ann Surg Oncol 1994;1:773–778.
Lillemoe K, Imbembo AL. Malignant neoplasms of the duodenum. Surgery 1980; 150:822–826.
Cortese AF, Cornell GN. Carcinoma of the duodenum. Cancer 1972;29:1010–1015.
Moss WM, McCart PM, Juler G, Miller DR. Primary adenocarcinoma of the duodenum. Arch Surg 1974; 108:805–807.
Kaiser MH, Ellenberg SS. Pancreatic cancer. Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985;120:889–903.
Gastrointestinal Tumor Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59:2006–2010.
Crist DL, Sitzmann JV, Cameron JL. Improved hospital morbidity, mortality, and survival after the Whipple procedure. Ann Surg 1987;206:358–365.
Trede M, Schwall G, Saeger H. Survival after pancreaticoduodenectomy. 118 consecutive resections without a mortality. Ann Surg 1990;221:447–458.
Geer RJ, Brennan ME. Prognostic indicators for survival after resection of pancreatic adenocarcinoma. Am J Surg 1993; 165:68–73.
Cameron JL, Pitt HA, Yeo CJ, Lillemoe KD, Kaufman HS, Coleman J. One hundred and forty-five consecutive pancreaticoduodenectomies without a mortality. Ann Surg 1993; 217:43–49.
Nakeeb A, Pitt HA, Sohn TA, Coleman JA, Abrams RA, Pi-antadosi S, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Cholangiocarcinoma: A spectrum of intrahepatic, perihilar, and distal tumors. Ann Surg 1996;224:463–475.
Talamini MA, Moesinger RC, Pitt HA, Sohn TA, Hruban RH, Lillemoe KD, Yeo CJ, Cameron JL. Adenocarcinoma of the ampulla of Vater: A 28-year experience. Ann Surg 1997; 225:590–600.
Author information
Authors and Affiliations
Corresponding author
Rights and permissions
About this article
Cite this article
Sohn, T.A., Lillemoe, K.D., Cameron, J.L. et al. Adenocarcinoma of the duodenum: factors influencing long-term survival. J Gastrointest Surg 2, 79–87 (1998). https://doi.org/10.1016/S1091-255X(98)80107-8
Issue Date:
DOI: https://doi.org/10.1016/S1091-255X(98)80107-8